Clinical Trials Logo

Clinical Trial Summary

Natural killer/T-cell lymphoma (NKTCL) patients with relapsed/refractory disease had very poor outcome. Anti-PD-1 antibody showed promising results in response, but but the complete remission rate of was low. Some anti-PD-1 antibody based regimen showed higher and deeper response in NKTCL patients.


Clinical Trial Description

About 20-30% of early-stage patients and 40-60% of late-stage NKTCL patients will experience disease relapse and refractory disease, and the median survival time of relapsed patients is about 6 months. PD-1 antibody is an effective drug for the treatment of patients with relapsed/refractory NKTCL, but the response rate and complete remission rate of monotherapy are low. How to improve the prognosis of patients is an important way to try combination therapy. In this study, we aim to explore the effectiveness and safety of a novel anti-PD-1 antibody, tislelizumab, in combination with different drugs (tislelizumab plus azacytidine and lenalidomide, or tislelizumab plus etoposide and pegaspargase) to treat refractory NK/T. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05058755
Study type Interventional
Source Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact
Status Completed
Phase N/A
Start date September 17, 2021
Completion date December 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT06314334 - Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma Phase 2
Completed NCT03618238 - Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma Phase 2
Recruiting NCT04004572 - Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma Phase 2
Recruiting NCT03623087 - SIMPLE Chemotherapy for NK Lymphoma/Leukaemia Phase 3
Recruiting NCT03107962 - Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma Phase 2
Recruiting NCT03630731 - Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma Phase 2
Completed NCT03936452 - Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma Phase 2
Recruiting NCT04366128 - Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL N/A